<DOC>
	<DOCNO>NCT02279745</DOCNO>
	<brief_summary>This study open-label extension study determine long-term safety tolerability APD811 patient WHO Group 1 PAH complete Phase 2 study , APD811-003 . Patients must complete APD811-003 study must meet eligibility criterion APD811-007 .</brief_summary>
	<brief_title>Long Term Safety Efficacy APD811 Pulmonary Arterial Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<criteria>Evidence personally sign date informed consent document Is willing able comply schedule visit , treatment plan , laboratory test , study procedure deem appropriate candidate participation longterm extension study administration APD811 Fulfilled eligibility criterion APD811003 complete study plan Patients discontinue clinical worsening APD811003 assign placebo complete end study procedure include right heart catheterization ( RHC ) may participate data APD811003 study clean locked Patients enrol APD811003 withdrawn study drug treatment due AE , SAE , clinical worsening assign APD811 , patient complete APD811 003 study reason . Female patient wish become pregnant Systolic BP &lt; 90 mmHg Baseline/Day 1 Other severe acute chronic medical laboratory abnormality may increase risk associate study participation investigational product administration may interfere interpretation study result , judgment investigator , would make patient inappropriate entry study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>